Administration of exogenous glucocorticoids is known to suppress the HPA axis and has been reported to occupy brain glucocorticoid receptors, eventually leading to down-regulation. To determine the effects of chronic corticosterone administration on HPA axis function, corticosterone was administered as both 25% and 50% corticosteronekholesterol pellets. Rats were sacrificed 6 days after corticosterone pellet implantation. The 25% corticosterone pellets produced a small increase in morning corticosterone concentrations but no change in evening ACTH or corticosterone secretion. The 50% corticosterone pellets produced constant corticosterone concentrations of 5-6 pg/dl, with no circadian variation in corticosterone, indicating inhibition of evening ACTH and corticosterone secretion. The 25% corticosterone pellets produced no significant decrease in thymus weight or in adrenal weight; 50% corticosterone pellets produced significant decreases in thymus weight and adrenal weight. Neither 25% nor 50% corticosterone pellets produced significant decreases in GR in hippocampus and cortex. The 50% corticosterone pellets treatment resulted in a decrease in anterior pituitary POMC mRNA levels, a decrease in baseline and oCRH stimulated ACTH release from the anterior pituitary, and a near complete inhibition of the AM and PM response to restraint stress. These results suggest that: 1) the HPA axis was able to adjust to the small increase in glucocorticoids produced by the 25% cort pellets with minimal disturbances in function and 2) 50% corticosterone pellets exert a significant inhibitory effect on stress and diurnal ACTH secretion which appears to be exerted at the pituitary as well as possible inhibitory effects on brain.
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Glucocorticoid secretion is tightly controlled by an elaborate systems of checks and balances. In particular, the circulating concentrations of glucocorticoid 'feedback' to the controlling elements at multiple levels to turn off glucocorticoid secretion and consequently maintain the right range of glucocorticoids ( 1, 2 ) . In man, administration of exogenous glucocorticoids clearly suppresses endogenous glucocorticoid secretion, resulting in adrenal atrophy with prolonged administration (3) . Although exogenous glucocorticoids suppress cortisol or corticosterone and ACTH secretion, whether the site of feedback inhibition is the brain or pituitary is less clear. Dexamethasone, a synthetic glucocorticoid commonly used to monitor the 'normality' of the feedback circuits, appears to exhibit particularly profound inhibitory effects on the pituitary corticotrophs, and most data suggest that its primary site of negative feedback action is the pituitary (4, 5. 6) .
Circadian variation of corticosterone secretion is the normal pattern in a number of species including rat and man. The circulating levels of glucocorticoids show a circadian rhythm with peak and trough levels varying an order of magnitude (3, 7, 8, 9) . The circadian variation in cortisol secretion is believed to reflect the circadian pattern of corticotropin releasing factor (CRF 1 from the paraventricular nucleus. Patients suffering from Cushing's disease, an ACTH secreting corticotroph tumor, generally demonstrate an absence of a circadian rhythm in ACTH or cortisol secretion, presumably because the tumor secretion is independent of CRH input and the high concentration of circulating glucocorticoids inhibit the neural elements responsible for CRH secretion which drives the circadian rhythm of cortisol. (3) In contrast, patients suffering from depression, a disorder that stimulates HPA axis activation through neural pathways, often demonstrate hypercortisolemia with elevated plasma glucocorticoid secretion at both the zenith and nadir of the circadian rhythm (10) (11) (12) (13) (14) . Whether these two different patterns of glucocorticoid secretion exert different effects on brain is not known. Although brain glucocorticoid receptors (GR) are traditionally measured following adrenalectomy, the number of cytosolic GR can also be measured in non-adrenalectomized rats. When measured in intact rats this number of cytosolic receptors in hippocampus and cortex reflects the number of non-translocated receptors and can be used to determine the effects of in vivo manipulations such as acute stress, acute glucocorticoid administration or diurnal changes over the circadian rhythm (15, 16, 17, 18) . Elegant studies by Miller et al. have characterized this method as a means of determining receptor occupation following administration of dexamethasone and corticosterone ( 17) . Consequently, measurement of GR in adrenally intact rats may be useful as an index of glucocorticoid receptor occupation and provide information on whether a feedback signal is being exerted primarily at the brain. The following studies were undertaken to compare the effects of different doses glucocorticoids administered as a continuous corticosterone pellet on neural and peripheral elements of the HPA axis, including receptor activation. Corticosterone was chosen as the glucocorticoid to be administered since it has high aflinity for both mineralocorticoid receptors ( M R ) and glucocorticoid receptors ( G R ) in the brain, in contrast to the synthetic ligand dexamethasone which binds poorly to MR. Previous studies by us and others had characterized the effects of the continuous release pellets used as replacement doses in adrenalectomized rats on plasma ACTH and corticosterone. and glucocorticoid and mineralocorticoid binding ( 2 . 19, 20) . However, the plasma corticosterone levels achieved and the pattern of adaptation arc likely to be different in adrenally intact animals from that shown in adrenalectomized animals. Consequently, the current studies were undertaken to explore how the HPA axis as a system adapts to an increase in glucocorticoids administered as a slow release corticosterone pellet, and a t what levels of the HPA axis the feedback signal may be active.
Results

T~vc~rzt~v-firr per cent pellet esperiments
The effect of implantation of 25% corticosterone pellets were explored first. By day 6 following pellet implantation, plasma
corticosterone levels were low in the a.m. of the cholesterol pellet rats ( 1.55 f0.6 pg/dl) and very slightly increased in the corticosterone pellet rats (3.4f0.8 pg/dl). The plasma corticosterone levels in the p.m. were identical in the two groups (12.7 ,ug/dI in both groups). Plasma ACTH and corticosterone data are shown in Figure 1 . There was a significant a.m./p.m. difference in plasma ACTH, but no effect of corticosterone pellet treatment on plasma ACTH. Neither adrenal weight nor thymus weight, a sensitive index of integrated glucocorticoid concentrations in the periphery, was significant decreased in the rats receiving 25% corticosterone pellets. There were no differences in body weight between cholesterol and corticosterone pellet rats. Pituitary ACTH content and POMC mRNA levels were unchanged by 25°/;! corticosterone pellet treatment. There were no significant effects of 25% corticosterone pellets on G R in hippocampus, cortex or hypothalamus (Table 1 ). The K,s from Scatchard analysis were very similar for both groups in the cortex and hippocampus (2.2 & 0.2 nM for sham and 2.4f0.3 n M cort in the cortex and 3.3k 1.3 nM for sham and 2.6k0.7 nM in the hippocampus). There were no detectable mineralocorticoid receptors in any brain region from either group of rats.
Fifty per cent corticosterone pellets
Implantation of 50% corticosterone pellets resulted in very different hormonal profiles than 25% pellets. The data are shown in Table 2 ). There was no significant effect of corticosterone pellet treatment on CRH mRNA in the PVN, but there was a significant effect of dex treatment ( Table 2 , Cort Rx F=0.9, d f = l . p=ns; dex Rx F=9.3, P=O.O07). The pituitaries from these rats were processed into single cell suspensions and then challenged with 1 nM ovine corticotrophin releasing factor (oCRF). The pituitaries from 3 rats were pooled for these challenge studies. A total of 6 animals per group was examined and data are the means of both pools. Anterior pituitary cell preparations from the 4 groups of rats were challenged with 1 nM oCRH. The data are shown in Fig. 3 .
Chronic corticosterone pellets reduced the baseline and oCRH stimulated ACTH secretion, but the responsiveness to oCRH, expressed as per cent unstimulated baseline is the same in both groups (150%). Acute dex treatment and the combination of acute dex plus cort pellets produced decreases in both ACTH Fig. 2 , panel A. By day 6, the 50% pellet rats clearly demonstrate an inhibition of the normal p.m. rise in corticosterone, suggesting a flat circadian rhythm of corticosterone, while cholesterol pellet controls demonstrate a normal circadian rhythm of corticosterone. The plasma ACTH data also demonstrated a clear circadian rhythm of ACTH in the rats treated with cholesterol pellets.
( Fig. 2 
FIG. 3 .
Anterior pituitary cell baseline secretion and response to oCRH following in vivo treatment with either 50% corticosterone pellets, dexamethasone in the drinking water, or the combination. All 3 treatments result in a decrease in baseline ACTH secretion in comparison to placebo treated control rats. The percent increase in ACTH secretion following oCRH stimulation is similar between control and 50% corticosterone treated rats ( 15O'Yo). Dexamethasone treatment appears to inhibit responsiveness to oCRH (127% and 110%) for dex and dex plus cort rats respectively). H baseline; + oCRF.
secretion and responsiveness to oCRH, expressed as percent unstimulated secretion ( 127Yn and 110% respectively).
To determine if the failure of 50% corticosterone pellets to produce a decrease in CRH mRNA might occur because corticosterone was too weak an agonist at GR, a comparison of acute dexamethasone and acute corticosterone was undertaken. Because of the high concentration of corticosterone in this solution (200 pg/ml) each rat consumed approximately 1.6 mg of corticosterone. The plasma corticosterone concentration in rats receiving corticosterone in the drinking water was elevated to the concentration normally seen during the peak of the circadian rhythm in the corticosterone treated rats (Table 3) confirming an adequate intake of corticosterone (One way ANOVA F = 19.6, P=0.0001; P<0.05 Fisher PLSD post-hoc water vs cort). Likewise, the plasma corticosterone concentrations in the dexamethasone treated rats were suppressed below the very low morning baseline ( Finally, two additional experiments were undertaken. The first was conducted to determine whether implantation of a sham pellet may have altered our ability to detect the effects of 50% corticosterone treatment. Hippocampal and cortical G R were measured in a third group of 50% corticosterone treated rats and compared to a group of unhandled control rats. Again, identical numbers of G R were seen in unhandled control and 50'% corticosterone treated rats in both hippocampus and cortex. To increase the statistical power to detect small decreases in GR, the receptor binding data from all 3 studies were combined for statistical analysis and still no significant decrease in G R number was observed in hippocampus or cortex (Hippocampus Control = 82.5 & 1 1, Hippocampus Cort = 85.8 & 16; Cortex Control = 85 & 13, Cortex Cort = 94 f 10). The final experiment evaluated whether the lack of effect of 50% corticosterone pellet treatment on G R binding was specific to the brain, or also occured in peripheral tissues. We examined GR binding in spleen, thymus and anterior pituitary. No significant decreases in G R binding were seen in any tissue examined, whether central or peripheral.
Effect of 50% coi*ticostemw pelle fs on stress-induced A CTH secretion Since the 50% corticosterone pellet rats demonstrated an inhibition of diurnal ACTH secretion, the ability of this treatment to affect restraint stress induced ACTH secretion in both the a.m. and p.m. was explored. In this study, each rat was studied in the a.m. and p.m. both before and after 50% corticosterone pellet implantation. The plasma ACTH data for 5 and 30 mins of restraint stress are shown in Fig. 4 . As can be seen, there was a 
Discussion
The data presented here describe two different doses of chronic corticosterone that lead to different plasma corticosterone profiles and different adaptations on the part of the HPA axis. The 25%) corticosterone pellets resulted in an increase in the morning corticosterone but preservation of the circadian rhythm of corticosterone while 50% corticosterone pellets produced an inhibition of the normal evening rise in plasma corticosterone, suggesting a flat circadian rhythm of corticosterone, although a shift in timing of the peak cannot be excluded with only two time points of sampling. In both the 25'% and 50'% pellet experiments, the cholesterol pellet controls rats demonstrated morning corticosterone concentrations of 1.5 pg/dl; the 25% pellet rats demonstrated morning corticosterone concentrations of 3.4 pg/dl, while the 50% corticosterone pellet rats demonstrated morning corticosterone concentrations of 5.6pg/dl. The small increase in a.m. plasma corticosterone in the 25% corticosterone pellet rats did not lead to any change in the evening plasma ACTH or corticosterone secretion, while the additional increment in plasma corticosterone in the 50'% corticosterone pellet rats led to a significant suppression of a.m. plasma ACTH concentrations, and a suppression of the diurnal rhythm of ACTH and corticosterone secretion. The 25% pellets did not lead to a significant decrease in thymus weight or adrenal weight. Similarly, there were no changes anterior pituitary ACTH content nor in POMC mRNA levels. These data suggest that the HPA axis was able to adapt to the small increase in morning corticosterone with few, if any, consequences. This was in clear contrast to the effects of 50% pellet administration, which led to a significant decrease in both thymus weight, and adrenal weight as well as a decrease in anterior pituitary POMC mRNA levels and the suppression of the evening circadian peak of ACTH and corticosterone secretion. However, even the 50"/0 corticosterone pellet treatment did not lead to a decrease in ACTH anterior pituitary content. In the 50% corticosterone pellet treated rats, both release, as reflected by plasma ACTH concentrations, and biosynthesis, as reflected by POMC mRNA levels, were decreased in parallel, which could explain the lack of change in ACTH stores. This suggests that steady state hormone stores are not the best indication of the activity of an endocrine gland.
In contrast to the clear indication of increased corticosterone concentrations in the peripheral measures of HPA axis function, there was no indication that either 25Yn or 50% corticosterone pellets produced any decrease in available G R (occupation or down-regulation) in hippocampus, cortex. hypothalamus, spleen or thymus. In second experiment G R and M R mRNAs in the hippocampus were measured and there was no indication that the chronic cort treatment produced receptor down-regulation at the mRNA level. This suggests that relatively high concentrations of circulating glucocorticoids may be necessary to produce significant occupation of Type I1 receptors, and that the corticosterone pellets never achieved this concentration. This hypothesis is supported by the data of Spencer ef al. (18) examining G R and MR occupation in intact rats during the peak and nadir of the circadian rhythm. as well as data from Reul et a1 examining the effects of acute stress on M R and G R occupation (21, 22) . In adrenally intact rats the increase in corticosterone from to 20 pgdl in the evening from 1 pgdl in the a.m. resulted in a 25% decrease in G R in the hippocampus and cortex. Given that the increases in plasma corticosterone concentrations resulting from the 5 0 % corticosterone pellets was only 25% of the normal diurnal change, a decrease of only 6'%, may be far too small to produce a detectable signal. Alternatively, the changes induced by chronic glucocorticoid treatment may be compensated by changes in the biosynthesis, half-life or distribution of receptors, so that available cytosolic receptors d o not appear to produce meaningful information following chronic treatment. Finally, the inability to detect decreases in G R and MR mRNA levels in whole hippocampus may reflect regional specific regulation of these mRNAs in hippocampal subfield. as already been reported for adrenalectomy induced increases (23) . Despite our inability to demonstrate any effects of corticosterone pellet treatment on G R , the small increase in glucocorticoids with this treatment resulted in inhibition of anterior pituitary POMC mRNA levels and inhibition of plasma ACTH secretion in both the a.m. and p.m..
In the Spencer et al. study (18) , a small number of M R could be detected in adrenally intact rats in the a.m. but not the p,m. In these current studies, M R could not be detected in any groups of rats, even the control rats with plasma corticosterone concentrations of 1.5 pg/dl or lower. This suggests either that these receptors are present in extremely small numbers in intact rats of this strain, or that these low levels of corticosterone are capable of fully occupying these receptors (21) . In neither dexamethasone experiment could we detect M R binding in the dexamethasone treated groups. This is rather surprising since Spencer et al. (15) demonstrated that this same dose of dexamethasone was able to lead to an increase in M R signal in non-adrenalectomized rats. Since the data of that group suggest that higher doses of dexamethasone in the drinking water will decrease M R binding, it may be that in the studies of Spencer et al. (15), the rats consumed less dexamethasone than in either of these two experiments. Because occupied MR in the nucleus cannot rebind steroid hormones in exchange assays ( 1 5 ) , we cannot determine if the failure to detect these receptors in cytoplasm results from only a small total pool of receptors or whether the majority of receptors are occupied and translocated to the nucleus. It should be noted that the studies of Reul et al. (22, 24, 25) found that the acute injection of dexamethasone produced no increase in M R binding for a full 24 h, even though the injection blocked the evening rise in corticosterone. Chronic dosing of corticosterone produced an increase in M R binding as well as a decrease in G R binding. Although GR and M R mRNA levels may be helpful in determining whether receptor down-regulation has occurred, our previous studies found no change in M R or G R mRNA levels in response to injection of corticosterone in sesame oil, a paradigm (20) a paradigm previously demonstrated to produce glucocorticoid receptor down-regulation (26). However. it is possible that regional changes in G R or M R mRNA levels in hippocampal subfields may occur as has been demonstrated for adrenalectomy (23) . Finally, steady state mRNA levels d o not always reflect changes occuring at the level of transcription and translation.
Chronic corticosterone treatment had no effect on CRH mRNA levels in the PVN, while acute dexamethasone administration did. Since dexamethasone is a synthetic steroid with a higher affinity for G R than corticosterone, it was possible that corticosterone is too weak of a G R agonist to affect binding and CRH mRNA. To test this hypothesis, we administered a high dose of corticosterone overnight in the drinking water similar to that given by Miller and colleagues (, 17) . These experiments were designed to demonstrate that a higher plasma corticosterone concentration (18 pgldl) was capable of affecting the central measures of glucocorticoid inhibition, since these effects were not seen with 50%) corticosterone pellets (5-6 pg/dl ). The plasma concentration of corticosterone achieved by this paradigm is similar to the plasma concentration during the circadian peak of corticosterone secretion. In the acute dexamethasone and acute corticosterone experiment, both steroids demonstrated clear inhibitory effects on basal ACTH secretion, even though the morning is normally the time of the trough in ACTH secretion in rats. Neither treatment led to a decrease in anterior pituitary POMC mRNA, probably because 12 h is too short of a time to lead to significant decreases in a large pool of mRNA. Both acute treatments were able to decrease C R H mRNA in the PVN; the decrease seen with dexamethasone treatment was similar in both experiments (50%1 of control). Finally, the comparisons between acute and chronic treatments involve both differences in absolute doses of steroids and differences in plasma corticosterone levels as well as differences in time course, so it is not possible to ascribe differences in HPA axis profiles produced by these different treatments to time course or dose alone
The 50% corticosterone pellet treated rats demonstrated clear inhibition of HPA axis but the sites of this inhibition are less clear. Corticosterone treatment blocks the normal evening rise of corticosterone, suggesting a t least a pituitary site of inhibition. The decrease in POMC mRNA further supports inhibitory effects at the pituitary. The decrease in baseline ACTH secretion and decreased ACTH response to 1nM C R F in 50% corticosterone pellet treated rats suggest that the pituitary is an important site of the negative feedback on ACTH secretion. particularly by decreasing readily releasable stores of ACTH. The similar response to oCRF. expressed as percent baseline, between anterior pituitaries from cholesterol treated and corticosterone treated rats suggest that the changes d o not involve changes in pituitary C R F receptors. Despite a clear decrease in POMC mRNA, there were no changes in CRH mRNA in the PVN in the 50%) corticosterone treated animals. Both CRH and vasopressin in the parvocellular division of the PVN are known to be secretagogues in the HPA axis. The current studies do not address vasopressin mRNA levels in the PVN because there are a large number of magnocellular vasopressin neurons within the micropunch area and these magno-experiments examined these same measures on day 6 in the a.m. In the repeat 50% corticosterone pellet experiment. a total of 12 rats received corticosterone pellets and 12 rats received cholesterol pellets. Five days following the implantation of the pellets, half of each group was given dexamethasone 1.5 pg/ml overnight in their drinking water (water was changed at 16.00). The other half of the rats were given normal drinking water.
All rats were sacrificed the following morning. A repeat experiment for acute dexamethasone consisted of overnight dexamethasone administration in the drinking water (1.5 pg/ml) to 6 rats, overnight corticosterone administration in the drinking water (200 pg/ml) to 6 rats and normal drinking water in the control rats. All rats were sacrificed the following morning. A repeat experiment consisted of overnight dexamethasone administration in the drinking water (1.5 pg/ml) to 6 rats, overnight corticosterone administration in the drinking water (200 pg/ml ) to 6 rats and normal drinking water in the control rats. Again, all rats were sacrificed the following morning and all hormone measures are from those time points.
In vivo experiments examining a.m. and p.m. stress responsiveness utilized a repeated measure design. Each animal was exposed to 30 min of a.m. and p.m. restraint (separated by 3 days) before implantation of the 50Y0 corticosterone pellets. Blood for ACTH and corticosterone was obtained by tail nick into non-heparinized capillary tubes. Following the time 0 sample (corticosterone only), a drop of dilute heparin-saline (1000 u/ml) was placed over the cut. The 5 and 30 min samples were collected from the same nick. Immediately following filling of each capillary tube, the sample was transferred from the capillary tube into an EDTA solution to prevent clotting.
Tissue processing
Trunk blood was collected in K+EDTA containing tubes on ice, centrifuged immediately, the plasma separated and acidified with IN HCl, then frozen on dry ice. It was subsequently stored at -70°C until extraction. Brains were removed from the skull, dissected on ice into the following regions: hippocampus, cortex overlying the hippocampus, and hypothalamus. These regions were frozen immediately on dry ice and stored at -70°C until the day of assay. To avoid contamination of the anterior lobe of the pituitary by intermediate lobe melanotrophs, the neurointermediate lobe of the pituitary was removed from the anterior lobe, and the portions of the anterior lobe contacting the intermediate lobe was discarded. The anterior lobe fragments were then frozen on dry ice and stored at -70°C until extraction. For anterior pituitary in vitro challenge studies, anterior pituitaries from 3 animals were pooled, processed into single cell suspensions using collagenase treatment, and challenged with oCRF using the methods previously described (29) . Aliquots of the single cell suspension containing 250,000 cells were incubated with either medium alone or 1 nM oCRF for 60 min at 37°C under 950/00,, 5"/oco,. All samples were run in triplicate. At the end of the hour, the cell suspensions were centrifuged, the media collected for assay, and the the cells were extracted with GITC extraction described below. Thymuses were collected into 24 well microtiter plates with a small amount of isotonic saline, blotted on weighing paper, then weighed on the same day as the experiment. Adrenals were treated similarly; the outer capsulc and fat was removed before weighing.
Hormonal assays
Plasma samples were extracted with Sep-Pak C,, cartridges using our previously described procedure (30) . Samples were assayed for corticosterone using an RIA with our own antibody to corticosterone. This RIA is very specific for corticosterone and cross-reacts less than 2% with cortisol or 1 1-deoxycorticosterone. The assay buffer is 50 mM sodium phosphate containing 2.5% bovine serum albumin, pH 7.5. Following extraction the samples are re-suspended in assay buffer and two dilutions, the equivalent of 2 p1 and 5 pl of plasma are compared to determine which reads in the linear range of the curve. [3H] corticosterone was used as the radiolabeled ligand. Bound and free were separated by the addition of a charcoakdextran mixture (1% : O.l'!h) and centrifugation at 3000 x g. The assay sensitivity is 0.5 pgldl. Samples were assayed for ACTH by 2 methods, an RIA using our own antibody raised to ACTH 11-24. and the Allegro HS ACTH kit (Nichols Institute, San Juan Capistrano, CA. USA). Because the ACTH samples were extracted, 25 pl aliquots containing the equivalent of 250 p1 of plasma that were resuspended in 0.1% HSA were diluted to 200 p1 using the equine serum zero standard provided cellular neurons are not sensitive to glucocorticoid regulation (27). Thus it is possible that changes in vasopressin mRNA levels occur within the parvocellular division in our 50% corticosterone treated rats. Given the clear inhibition of the HPA axis, including both circadian and stress induced ACTH secretion, the decrease in ACTH secretion from anterior pituitary in vitro, and the decrease in anterior pituitary POMC mRNA levels resulting from 50% corticosterone pellet treatment, the pituitary as a site of inhibition has some experimental support.
Recent studies by Akana et al. ( 2 8 ) used a similar corticosterone pellet regimen of 20%, 40% and 80% corticosterone pellets. They observed with the 20% and 40% corticosterone pellets results that are comparable to our results with 25% and 50% corticosterone pellets on thymus weight, adrenal weight and peripheral plasma corticosterone concentrations, including the suppression of the circadian rhythm of corticosterone in the 40% corticosterone treated animals but not in the 20% corticosterone treated animals. They also observed a decreased ACTH and corticosterone response to restraint stress in the a.m. with 40% corticosterone pellet treatment. The same stress repeated in the p.m. resulted in an inhibition of the ACTH stress response only in the 80% corticosterone pellet group, demonstrating an a.m./p.m. difference in the effectiveness of the 40% corticosterone pellets in inhibiting HPA axis activation by stress. Our data with 50% corticosterone pellets demonstrate clear inhibition of the stress response in both the a.m. and p.m.. Differences between our data and their data probably result from higher plasma corticosterone levels (average 6.2 pg/dl) in the 50% corticosterone treated rats compared to their 40% corticosterone treated rats (4.0 pg/dl).
In conclusion, exogenous 50% corticosterone pellets caused profound inhibition of the HPA axis, but did lead to no detectable occupation of GR in the hippocampus, cortex, thymus or spleen. Thus it appears that examining the number of available cytosolic glucocorticoid receptors was not informative in this paradigm, probably because of the long term nature of the treatment. Given the data suggesting clear inhibition of the stress response in vivo, and inhibition of the anterior pituitary secretion in vitro, both pituitary and brain appear to be likely sites of the inhibitory effects of this treatment.
Methods
All studies were approved by the university committee on the use and care of animals. All studies were conducted on male Sprague Dawley rats obtained from Charles River (Portage, MI, USA), weighing 150-200 gs at the time of their arrival. All rats were given a minimum of one week to adapt to the stress of shipment before any experimental manipulations were initiated. All rats were maintained on a 12 h light/dark schedule and were given food and water ud libitum. All animals were group housed (6/cage) for these experiments. Rats sacrificed in the morning were within 3 h of 'lights on' and those in the evening within 2 h of 'lights o f f ' , but always during the lights on period. Exogenous corticosterone was administered as a 100 mg corticosterone/cholesterol pellet implanted subcutaneously under metofane anesthesia as described by Dallman et a/. (2) .
Experimental Design
These experiments involved the implantation of either 25% or 50'% corticosterone/cholesterol pellets (100 mg total) in the experimental group, and cholesterol pellets (100 mg) in the control animals on day 0. Animals were sacrificed at 2 times, day 6 in the morning and evening. Each group consisted of 6 rats. At each time trunk blood and pituitaries were collected for hormonal assays, brains for glucocorticoid receptor assays and adrenals and thymuses for weight determination. Subsequent by the kit. p-endorphin was assayed using the previously described assay (24, 25) . This antibody recognizes fully both 0-lipotropin and P-endorphin. and thus gives a reliable index of corticotrope secretion.
Anterior pituitaries were extracted using a guanidium-isothiocyanate (GITC) extraction. Tissue were homogenized through a 26 Ga needle in 300p1 of GT buffer (guadinium isothiocyanate (5M), 10mM EDTA, 50 mM Tris, 8% mercaptoethanol). Five volumes of 4M LiCl were added and the samples were precipitated overnight at 4°C. Following centrifugation. the supernatant containing proteins was further extracted by SepPak extraction, lyophilized and then assayed for ACTH using the radioimmunoassay previously described. (25) This assay utilizes an antibody raised to ACTH 11-24. which recognizes ACTH and larger molecular weight forms (22K and POMC) but not alpha-MSH. The pellet containing nucleic acids was digested with 300 pI of proteinase K (150 pg/ml) solution. and then mRNA was precipitated in ethanol at -20°C for subsequent POMC mRNA quantitation. Approximately 3 pg of total RNA was loaded on a I % ~g~~o s e~o~~~l d e~y d e~e l and electmphoreseded for 6-8 h, then blotted onto Nytran membrane (0.45 pM) overnight. Membranes were probed with a 32P labeled cRNA probe transcribed from a full length rat POMC cDNA (960 bp. Eberwine) and apposed to autoradiographic film. Appropriate size bands on the X-ray film were quantitated by optical density and normalized to total ribosomal RNA, as determined by an 35S labeled ribosomal RNA probe of the same membrane. or normalized to PI B15 mRNA (corticosterone injection experiments), A 2 rnm section through the hypothalamus containing the paraventricular nucleus (PVN) was dissected using a brain block slice with subsequent removal of tissue lateral to the PVN. The hippocampus and frontal cortex were dissected from the region caudal to the hypothalamic slice. All tissue was frozen immediately on dry ice and stored at ~ 80°C until subsequent extraction. The RNA was extracted from the anterior pituitary, paired PVN, and one hippocampus from each animal using a guanidium isothiocyanate extraction (GITC). Tissues were homogenized in buffer containing 5M GITC, 10mM EDTA, 50mM Tris HC1 (pH 7.5), 8% (v/v) P-mercaptoethanol, then precipitated with 5 volumes of 4M LiCl at 4°C. The precipitates were pelleted by centrifugation and treated with proteinase K (lOOpg/ml in 0.5% SDS, 50mM Tris HC1) for 1-2h at 37'C. The samples were extracted by phenol-chloroform then precipitated in EtOH. Following EtOH precipitation, RNA samples from the PVN and the hippocampus were used in a RNAse protection assay as previously described (19) . Briefly, A 751 bp fragment of the rat CRF cDNA (provided by A. Seasholtz) was transcribed to yield a cRNA probe labeled with 3ZP-UTP. The rat glucocorticoid receptor clone spanning 450 bp of the 3' untranslated Ranking sequence was used as a template for cRNA synthesis. The rat mineralocorticoid receptor DNA was a 550 bp fragment of the 3' translated and untranslated region. These probes were added to the respective hybridization mix (400 mM PIPES pH 6.4, 0.4 M NaCl. 1 mM EDTA. 50% formamide) containing 1/3 of the RNA extracted from paired PVN from each rat, or from one hippocampus of each rat. Hybridization takes place for 14-16 h at 55°C. RNAse A, 10 pg/ml was added and incubated for 15-30 min at room temperature. RNAse is neutralized by addition of 1% SDS and proteinase K for 30 min at 37°C. The samples were then precipitated in EtOH, resuspended in 20% formamide and separated on a 4%) polyacrylamide gel. The gel was apposed to X-ray film (Kodak X-ar) and resulting bands quantified by densitometry.
Glucocortiroid receptor assays
For measurement of GR in brain, single point assays on one hippocampus and one cortex of each animal were performed using a saturating concentration of ligand ( 10 nM [3H]-dexamethasone) to quantitate binding for each animal (17, 18, 30) . 500 nM RU 26988, a specific Type I1 (GR) agonist, was used to determine GR binding and 2.5 pM corticosterone was used to determine non-specific binding. The other hippocampus and cortex from each animal of the same group were pooled for Scatchard plot binding data (experiment 1 only). For hypothalamus, single point assays alone were performed. For the actual binding assay, frozen regions were homogenized with 15 strokes in a hand held glass homogenizer in lOmM ice cold Tris buffer, pH 7.4, with 1 mM EDTA, 10% glycerol, 20 mM molybdate. and 1 mM dithiothreitol. The homogenate was centrifuged at 40,000 rpm in an ultracentrifuge with T 1-50 rotor for 30 min. then the cytosol (supernatant) was transferred with pasteur pipette to a glass test tube and remained on ice until addition of labeling ligand. For Scatchard plot analyses, an aliquot of the cytosol (100 pl) was incubated with increasing concentrations of [3H] dexamethasone (0.1-10 nM) with and without 500nM RU 26988 (a specific Type I1 antagonist). Excess (2.5 p M ) corticosterone was used to determine specific total binding (MR plus GR). The samples plus radiolabelled ligand are incubated overnight at 0°C then bound [3H] ligand is separated from free by use of LH-20 minicolumns (25% corticosterone pellet) or dextran coated charcoal (other experiments). The eluate from the minicolumn, which contains bound receptor-ligand complex, is collected directly into scintillation vials. scintillation cocktail is added and the samples are counted. Alternatively, following the addition of dextran coated charcoal, the incubation tubes were centrifuged, and the supernatant, containing bound receptor-ligand complex, was aliquotted into scintillation vials. and scintillation cocktail was added. All samples were run in triplicate, the triplicates were averaged, and fmoles bound were calculated. A small sample of the original cytosol was assayed for protein content with Bio Rad protein assay; the binding values are expressed as fmoles bound/mg protein.
